Actively Recruiting
LOG-I Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients / Study of LOG-AFTER's Effect on Long-term Follow-up of Cancer Survivors
Led by University Hospital, Angers · Updated on 2025-07-02
320
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Angers
Lead Sponsor
N
National Cancer Institute, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the impact of the LOG-AFTER software on long-term follow-up care for childhood cancer survivors, including those with brain tumors. This study focuses on personalized follow-up to detect complications that may affect quality of life or increase mortality risk. The LOG-AFTER software, developed in France, offers improved follow-up processes by linking patients and their general practitioners (GPs) and providing educational resources. Participants are randomly assigned to either use the LOG-AFTER software or receive usual care without the software. For those using LOG-AFTER, an account is created shortly after inclusion, allowing patients and their GPs to report examinations and consultations, ensuring personalized follow-up plans are up to date. Both groups complete questionnaires including the PAM-13, and follow-up is organized by their specialists or GPs. After three years, patients and GPs complete satisfaction surveys and updates to the personalized after-cancer plan (PPAC) are made as needed. During the study, data such as cancer type, treatment dates, and psychosocial information are collected. Patients complete the PAM-13 questionnaire at inclusion and again at 36 months. The study measures adherence to follow-up recommendations based on the PPAC over three years, patient and GP satisfaction, health status, software use, and patient empowerment. The total participation period spans three years with scheduled contacts and consultations to update follow-up plans and assess outcomes.
CONDITIONS
Brief Title
LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Previously treated for cancer or malignant hematological disease before age 25
- No active disease or stable disease without treatment for 5 years or more
- Owns a computer, smartphone, or tablet with internet access
- Has signed informed consent (or parents/third party if minor or necessary)
- Has 3 or more recommended screenings in personalized follow-up plan
- No previous active use of LOG-AFTER software within the last 24 months
You will not qualify if you...
- Relapsed or developed a second cancer with less than 5 years since treatment ended
- Not covered by health insurance
- Under legal protection, deprived of liberty by judicial or administrative decision, or under involuntary psychiatric care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit
Duration - Up to 3 years
Participants are monitored for long-term follow-up of cancer survivorship with or without the use of the LOG-AFTER software. Participants randomized to the software group create an account and regularly report examination completions, while general practitioners update consultation and examination information through the software.
Follow-up visits and contacts organized according to the habits of the specialist and/or general practitioner
Duration - 1 visit at 36 months (+/- 3 months)
Approximately 3 years after inclusion, participants are contacted or reviewed in consultation to update follow-up data and the Personalized After-Cancer Plan (PPAC) if needed. Satisfaction questionnaires and the PAM-13 questionnaire are completed by participants and general practitioners, with follow-up calls if necessary.
1 follow-up visit or contact
Trial Site Locations
Total: 1 location
1
University Hospital of Angers
Angers, Maine Et Loire, France, 49933
Actively Recruiting
Research Team
S
Sandra MERZEAU
P
Pascal VEILLON
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here